Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human pancreatic tumor cell lines - AsPC-1, PANC-1, MIA paca2, KP-1 and KP-59 cells - can be induced to differentiate into pancreatic hormone-producing cells by brief trypsin treatment and subsequent culture in a serum-free, chemically defined medium. During culture, AsPC-1 cells formed cell clusters resembling the pancreatic islets, expressed genes associated with the pancreatic development and produced
glucagon
but not insulin. When PANC-1, MIA paca2, KP-1 and KP-59 cells were treated and cultured the same way, they underwent similar morphological changes and produced insulin and
glucagon
. We used these systems to identify intracellular regulatory molecules involved in the conversion of pancreatic tumor cells into
glucagon
-producing cells. We found that the expression of
antizyme 1
(
AZ1
), a negative regulator of ornithine decarboxylase, was increased and its localization was altered from the nucleus to the cytoplasm during AsPC-1 cell differentiation. Transient transfection of AsPC-1 cells with
AZ1
siRNA resulted in inhibition of the morphological and functional cell differentiation as well as the specific suppression of
AZ1
expression. By contrast, constitutive overexpression of
AZ1
in AsPC-1 cells led to the enhancement of
glucagon
production. We also found that PANC-1 cells reduced the expression of
glucagon
mRNA when treated with
AZ1
siRNA. These results suggested that
AZ1
was necessary for the conversion of pancreatic tumor cells into
glucagon
-producing cells.
Glucagon
production in AsPC-1 cells was not affected by addition of putrescine, suggesting that the polyamines were not directly involved in the
AZ1
-mediated conversion of pancreatic tumor cells to differentiated state.
...
PMID:Antizyme is necessary for conversion of pancreatic tumor cells into glucagon-producing differentiated cells. 1934 29